Not every company is jumping onto the bandwagon and investing into weight loss drugs, however. One of the largest healthcare ...

Weight-loss supplements are rebranding as “GLP-1 boosters.” They’re nothing like Ozempic.

A review of the medical records of thousands of adolescents treated for obesity found that kids who received the GLP-1 ...

Telehealth sites prescribing GLP-1s online can get off the ground in a matter of days by “renting” the services of these ...

STAT reporters discuss investors' interest in autoimmune disease, GLP-1 supply issues, and big moments from #STATSummit.

Transenteric delivery via the RaniPill yielded 80% relative bioavailability versus SC and differences between PK parameters ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

Those who took Ozempic or a similar drug had a 40% lower chance of overdosing on opioids and a 50% lower chance of getting ...

While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.

Hims & Hers is revolutionizing healthcare with affordable, convenient telehealth services, leading to a 260% stock increase in the last year. Read more here.

Researchers estimate that expanding access to weight-loss drugs could save over 50,000 lives annually, reducing obesity rates ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) given to adolescents with obesity was associated with a one-third ...